Re: USA ZHCLF investors
in response to
by
posted on
Oct 30, 2022 04:16PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
The way I originally looked at this is that there will be A and B shares once Zenith put out an IPO.
The A shares would be the preferred shares with a dividend attached to them or a reasonable facsimile in favour of the original RVX shareholders for holding down the fort, so to speak. But it is what it is.
Koo